The CD30 antigen is expressed on HL and some anaplastic lymphomas, and Bre–Ved is a therapeutic tool for these diseases [27,28,29,30,31,32,33,34]. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.